Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 4/20 | 0.49 |
| ▸ | CNR2 | P34972 | 5/20 | 0.45 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 3/20 | 0.44 |
| ▸ | ABL1 | P00519 | 2/20 | 0.42 |
| ▸ | BCR | P11274 | 2/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 2/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3521916 | 0.95 | IKBKB (0.47) | IKBKBCNR2AXLCNR1ABL1 | |
| SCHEMBL3521723 | 0.89 | IKBKB (0.50) | IKBKBAXLABL1BCRNR4A1 | |
| SCHEMBL3521501 | 0.89 | IKBKB (0.50) | IKBKBABL1BCRNR4A1CDC7 | |
| SCHEMBL3516443 | 0.89 | CNR2 (0.51) | IKBKBCNR2CNR1CCNA2CDK2 | |
| SCHEMBL3521750 | 0.86 | IKBKB (0.65) | IKBKBCDK2 | |
| SCHEMBL3516749 | 0.86 | IKBKB (0.51) | IKBKBABL1BCRCDC7CDK19 | |
| SCHEMBL3521141 | 0.84 | IKBKB (0.49) | IKBKBABL1BCRCDC7CDK19 | |
| SCHEMBL3517971 | 0.84 | IKBKB (0.53) | IKBKBABL1BCRCDC7CDK19 | |
| SCHEMBL3516904 | 0.84 | IKBKB (0.49) | IKBKBABL1BCRCDC7CDK19 | |
| SCHEMBL4872194 | 0.84 | IKBKB (0.62) | IKBKBCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | claimed |
| EP-1799652-A1 | N-BENZENESULFONYL SUBSTITUTED ANILINO-PYRIMIDINE ANALOGS | Wyeth (US) | 2007-06-27 | — | — | EP | claimed |
| WO-2006044457-A1 | N-BENZENESULFONYL SUBSTITUTED ANILINO-PYRIMIDINE ANALOGS | WYETH (US) | 2006-04-27 | — | — | WO | claimed |
| US-20060079543-A1 | Anilino-pyrimidine analogs | WYETH (US) | 2006-04-13 | — | — | US | claimed |
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-20060079543-A1 | Anilino-pyrimidine analogs | WYETH (US) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079543-A1 | Anilino-pyrimidine analogs | DPYD, TYMP, ADORA3 | IKBKB 3246/4885CNR2 955/4885AXL 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.